Log In
Print
BCIQ
Print
Print this Print this
 

IL-17A inhibitor Ensemblin (E-036041)

  Manage Alerts
Collapse Summary General Information
Company Ensemble Therapeutics Corp.
DescriptionSmall molecule macrocyclic IL-17A antagonist identified using Ensemblin technology
Molecular Target Interleukin-17A (IL-17A)
Mechanism of ActionInterleukin-17 (IL-17) antagonist
Therapeutic ModalityMacrocycle
Latest Stage of DevelopmentPreclinical
Standard IndicationArthritis
Indication DetailsTreat arthritis
Regulatory Designation
Partner Novartis AG

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today